Tier 2 — strong

Effects of Coenzyme Q10 on Lipid, Glycemic, and Inflammatory Markers in Metabolic Disorders: A Systematic Review and Meta-Analysis

Zhuo Zhang, Zhuo Liu, Yuli Geng, Yanjing Huang, Runan Hu, Fan Li, Yufan Song, Mingmin Zhang
Journal of Diabetes Research 2026 2026(1):e5587445

Bibliography

PubMed
PMID 42192187
PubMed Central
PMC13212042
DOI
10.1155/jdr/5587445
Funding
Supported by the cooperation project of Integrated Chinese and Western Medicine of Refractory Diseases, Hubei Province.
Competing interests
The authors declared no conflicts of interest.

Study snapshot

DesignSystematic review and meta-analysis of randomized controlled trials
ModelSystematic review and random-effects meta-analysis of randomized controlled trials evaluating CoQ10 on lipid, glycemic and inflammatory biomarkers in metabolic disorders.
Sample64 RCTs; 3,422 participants. The included studies contributed outcome-specific subsets and approximately 74 trial arms across the evidence base.
InterventionCoQ10 doses ranged from 60 to 600 mg/day for 4–24 weeks. Most trials used ubiquinone; two used ubiquinol. Most tested CoQ10 monotherapy, while some combined CoQ10 with other interventions such as statins, fenofibrate or vitamin E.
Duration4–24 weeks across included trials.
EndpointsTriglycerides; Total cholesterol; HDL-C; LDL-C; HbA1c; Fasting glucose; Fasting insulin; HOMA-IR; CRP; TNF-alpha; IL-6; Subgroup analyses by disease, region, dose, duration, BMI, age and intervention type; Heterogeneity and sensitivity analyses

What the study showed, in plain terms

This 2026 systematic review pooled 64 randomized trials involving 3,422 participants with metabolic disorders. It is one of the broadest CoQ10 metabolic syntheses because it simultaneously assessed lipid, glycemic and inflammatory outcomes.

Average effects were statistically significant but generally modest for conventional lipids: triglycerides -5.67 mg/dL, total cholesterol -4.86 mg/dL, LDL-C -3.98 mg/dL and HDL-C +1.07 mg/dL. Glycemic outcomes also favored CoQ10: HbA1c -0.22 percentage points, fasting glucose -10.07 mg/dL, fasting insulin -2.94 µIU/mL and HOMA-IR -0.82.

Inflammatory markers showed pooled reductions in CRP, TNF-alpha and IL-6. However, heterogeneity was often substantial, certainty ranged from very low to moderate, doses/formulations varied widely, and some trials combined CoQ10 with other interventions. The authors’ 100–200 mg/day and ≥12-week subgroup pattern is therefore hypothesis-generating rather than proof of a universally optimal regimen.

Key findings

Lipids: TG WMD -5.67 mg/dL (95% CI -10.57 to -0.77; p=0.023); total cholesterol -4.86 (95% CI -8.41 to -1.30; p=0.007); HDL-C +1.07 (95% CI 0.22–1.92; p=0.013); LDL-C -3.98 (95% CI -7.00 to -0.97; p=0.010).

Glycemia: HbA1c WMD -0.22 percentage points (95% CI -0.37 to -0.06; p=0.006); fasting glucose -10.07 mg/dL (95% CI -14.75 to -5.39; p<0.001); fasting insulin -2.94 µIU/mL (95% CI -4.63 to -1.25; p=0.001); HOMA-IR -0.82 (95% CI -1.36 to -0.28; p=0.003).

Inflammation: CRP WMD -0.44 mg/L (95% CI -0.79 to -0.09; p=0.013; I²=90.9%); TNF-alpha SMD -1.01 (95% CI -1.56 to approximately -0.46; p=0.013; I²=68.6%); IL-6 SMD -0.42 (95% CI -0.79 to -0.05; p=0.027).

Trial diversity: metabolic populations included dyslipidemia, diabetes/IGT, PCOS, CAD, metabolic syndrome and NAFLD. Doses were 60–600 mg/day and duration 4–24 weeks. Most trials used ubiquinone; two used ubiquinol.

The review’s subgroup analyses suggested broader metabolic benefit around 100–200 mg/day and ≥12 weeks, but the authors explicitly described these findings as preliminary and requiring confirmation in high-quality randomized dose/formulation trials.

Evidence certainty across outcomes ranged from very low to moderate, and substantial heterogeneity persisted for many pooled estimates.

What this study can and cannot tell us

Very heterogeneous evidence base: metabolic diagnoses, baseline biomarker levels, CoQ10 dose (60–600 mg/day), formulation, treatment duration, geography and concomitant therapies varied substantially.

Some included trials tested CoQ10 alongside adjuncts such as statins, fenofibrate or vitamin E, so not every trial contributes a completely unconfounded estimate of isolated CoQ10.

Heterogeneity was high for several outcomes, including CRP (I²=90.9%) and LDL-C (I²=78.1%); subgroup analyses often involved small numbers and did not consistently identify the source.

Certainty ranged from very low to moderate rather than uniformly high. The review itself states that standardized formulations and larger high-quality RCTs are still needed.

The apparent 100–200 mg/day and ≥12-week ‘optimal’ pattern is based on between-trial subgroup comparisons, not a single definitive head-to-head dosing trial.

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology